Journal
MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 5, Issue -, Pages -Publisher
CELL PRESS
DOI: 10.1038/mtna.2016.5
Keywords
aptamer; microRNA; non-small cell lung cancer; TNF-related apoptosis-inducing ligand
Categories
Funding
- Associazione Italiana Ricerca sul Cancro, AIRC [ro 10620, ro 13345]
- MERIT [RBNE08E8CZ_002]
- POR Campania FSE, Project CREME
- Fondazione Berlucchi
- National Institutes of Health [R01CA138503, R21DE019953]
- Mary Kay Foundation [9033-12, 001-09]
- Elsa U Pardee Foundation [E2766]
- Roy J Carver Charitable Trust [RJCCT 01-224]
- 'Federazione Italiana Ricerca sul Cancro' (FIRC) Post-Doctoral Research Fellowship
- MERIT project Fellowship
Ask authors/readers for more resources
TNF-related apoptosis-inducing ligand (TRAIL) is a promising antitumor agent for its remarkable ability to selectively induce apoptosis in cancer cells, without affecting the viability of healthy bystander cells. The TRAIL tumor suppressor pathway is deregulated in many human malignancies including lung cancer. In human non-small cell lung cancer (NSCLC) cells, sensitization to TRAIL therapy can be restored by increasing the expression levels of the tumor suppressor microRNA-212 (miR-212) leading to inhibition of the anti-apoptotic protein PED/PEA-15 implicated in treatment resistance. In this study, we exploited a previously described RNA aptamer inhibitor of the tyrosine kinase receptor Axl (GL21.T) expressed on lung cancer cells, as a means to deliver miR-212 into human NSCLC cells expressing Axl. We demonstrate efficient delivery of miR-212 following conjugation of the miR to GL21.T (GL21.T-miR212 chimera). We show that the chimera downregulates PED and restores TRAIL-mediate cytotoxicity in cancer cells. Importantly, treatment of Axl+ lung cancer cells with the chimera resulted in (i) an increase in caspase activation and (ii) a reduction of cell viability in combination with TRAIL therapy. In conclusion, we demonstrate that the GL21.T-miR212 chimera can be employed as an adjuvant to TRAIL therapy for the treatment of lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available